Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer

Sponsor: Spectrum Pharmaceuticals, Inc.

A phase 2 trial of tyrosine kinase inhibitor poziotinib for patients with metastatic non-small cell lung cancer containing EGFR or HER2 exon 20 mutation that have undergone at least one prior line of therapy for metastatic disease.